AR083533A1 - Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe - Google Patents
Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripeInfo
- Publication number
- AR083533A1 AR083533A1 ARP110103916A ARP110103916A AR083533A1 AR 083533 A1 AR083533 A1 AR 083533A1 AR P110103916 A ARP110103916 A AR P110103916A AR P110103916 A ARP110103916 A AR P110103916A AR 083533 A1 AR083533 A1 AR 083533A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- treatment
- nucleic acid
- amino acid
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se provee además una molécula de ácido nucleico que codifica la proteína H5 del virus de la gripe, vector que comprende dicho ácido nucleico.Reivindicación 1: Proteína H5 del virus de la gripe, caracterizada porque la proteína H5 tiene (a) los aminoácidos 113D, 126H, 145(-), 156R, 160F, 167T, y 181N, en los que la modificación 145(-) significa que la posición del aminoácido 145 de H5 está delecionada, o (b) los aminoácidos 87P, 145L, 172T, 201E, 206I, 208K, 254T, 341G y 421K, o (c) los aminoácidos 145L, 172T, y 254V, y en los que la numeración de las posiciones de aminoácidos de la proteína H5 se refiere a la posición de aminoácido dada como ejemplo en la SEQ ID Nº 1, o (d) donde la proteína H5 comprende o consiste en una secuencia de aminoácidos que tiene al menos el 95%, preferiblemente al menos 96%, más preferiblemente al menos 97%, aún más preferiblemente al menos 98%, todavía más preferiblemente al menos 99%, o en particular preferiblemente el 100% de homología con una cualquiera de las secuencias indicadas en las SEQ ID Nº 2 a 40. Reivindicación 13: Una vacuna caracterizada porque comprende: a) la proteína H5 según una cualquiera de las reivindicaciones 1 a 10, la molécula de ácido nucleico según la reivindicación 11 o el vector según la reivindicación 12, y b) un vehículo y/o excipiente farmacéuticamente aceptable. Reivindicación 24: Un método para el tratamiento o la profilaxis de infecciones del virus de la gripe, caracterizado porque comprende la administración de una cantidad terapéuticamente eficaz de la proteína H5 según las reivindicaciones 1 a 10, a un sujeto que necesite dicho tratamiento, o donde el método comprende la administración de una cantidad terapéuticamente eficaz del ácido nucleico H5 según la reivindicación 11 o del vector según la reivindicación 12 a un sujeto que necesite dicho tratamiento, o donde el método comprende la administración de una cantidad terapéuticamente eficaz de la vacuna según la reivindicación 13 ó 14, a un sujeto que necesite dicho tratamiento, y donde en uno cualquiera de dichos métodos, la infección de gripe está causada en particular por un virus de la gripe aviar, porcina o humana o por cualquiera de sus combinaciones o híbridos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10188576 | 2010-10-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083533A1 true AR083533A1 (es) | 2013-03-06 |
Family
ID=43734836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103916A AR083533A1 (es) | 2010-10-22 | 2011-10-21 | Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2630155B1 (es) |
| CN (1) | CN103429611A (es) |
| AR (1) | AR083533A1 (es) |
| ES (1) | ES2798326T3 (es) |
| WO (1) | WO2012054907A2 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160287692A1 (en) * | 2012-11-16 | 2016-10-06 | Medimmune, Llc | Swine influenza hemagglutinin and neuraminidase variants |
| JP2016512680A (ja) * | 2013-03-15 | 2016-05-09 | ノババックス，インコーポレイテッド | ピコルナウイルス（Ｐｉｃｏｒｎａｖｉｒｕｓ）タンパク質の発現増強 |
| SG11201604996XA (en) * | 2013-12-23 | 2016-07-28 | Temasek Life Sciences Lab Ltd | Monovalent h5 vaccine |
| GB201507723D0 (en) * | 2015-05-06 | 2015-06-17 | Norwegian Univ Sci & Tech Ntnu | Anti-bacterial agents and their use in therapy |
| US20180128545A1 (en) | 2016-11-08 | 2018-05-10 | Berry Metal Company | Modular furnace cooling wall |
| EP3947406A4 (en) | 2019-04-05 | 2022-12-28 | Academia Sinica | SIALIDASE RESISTANT SACCHARIDE, METHOD FOR PRODUCTION AND USE |
| KR20230038416A (ko) | 2020-05-08 | 2023-03-20 | 아카데미아 시니카 | 키메릭 인플루엔자 백신 |
| MX2023000578A (es) | 2021-04-12 | 2023-04-26 | Academia Sinica | Vacuna mejorada contra el coronavirus. |
| TW202334429A (zh) | 2021-10-01 | 2023-09-01 | 中央研究院 | Sars-cov-2棘蛋白特異性抗體及其用途 |
| EP4412644A1 (en) * | 2021-10-06 | 2024-08-14 | DIOSynVax Ltd | Influenza vaccines |
| AU2024252371B2 (en) | 2023-04-08 | 2026-02-12 | Rock Biomedical Inc. | Methods and compositions for dendritic cell targeting nano-delivery |
| AU2024255035B2 (en) | 2023-04-08 | 2025-08-07 | Rock Biomedical Inc. | Methods and compositions for targeted delivery by polymersomes |
| WO2024238734A2 (en) | 2023-05-17 | 2024-11-21 | Rock Biomedical Inc. | Mgat1 deficient cells and uses thereof |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
| US4769331A (en) | 1981-09-16 | 1988-09-06 | University Patents, Inc. | Recombinant methods and materials |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| IL84154A0 (en) | 1986-10-16 | 1988-03-31 | Microgenesys Inc | Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same |
| US5811128A (en) | 1986-10-24 | 1998-09-22 | Southern Research Institute | Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| WO1990001543A1 (fr) | 1988-07-29 | 1990-02-22 | Intracel Corporation | Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo |
| CA2003300A1 (en) | 1988-11-21 | 1990-05-21 | Franklin Volvovitz | Skin test and test kit for aids |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| DE69034078T2 (de) | 1989-03-21 | 2004-04-01 | Vical, Inc., San Diego | Expression von exogenen Polynukleotidsequenzen in Wirbeltieren |
| US5591439A (en) | 1989-03-24 | 1997-01-07 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
| US5552143A (en) | 1989-03-24 | 1996-09-03 | The Wistar Institute Of Anatomy & Biology | Recombinant cytomegalovirus vaccine |
| US5690938A (en) | 1989-07-07 | 1997-11-25 | Oravax, Inc. | Oral immunization with multiple particulate antigen delivery system |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| GB9001766D0 (en) | 1990-01-25 | 1990-03-28 | Univ Court Of The University O | Vaccines |
| ATE162402T1 (de) | 1990-04-24 | 1998-02-15 | Flustat Pty Ltd | Oraler an der oberfläche von erythrozyten gebundene antigene beinhaltender impfstoff |
| KR100242671B1 (ko) | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
| US5997878A (en) | 1991-03-07 | 1999-12-07 | Connaught Laboratories | Recombinant poxvirus-cytomegalovirus, compositions and uses |
| DE69229390T2 (de) | 1991-08-26 | 1999-11-11 | Immuno Ag, Wien | Direkt molekuläre Klonierung eines modifizierten Genoms eines Chordopocken-Virus |
| US5382425A (en) | 1992-01-13 | 1995-01-17 | Syntro Corporation | Recombinant swinepox virus |
| US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| US5807722A (en) | 1992-10-30 | 1998-09-15 | Bioengineering Resources, Inc. | Biological production of acetic acid from waste gases with Clostridium ljungdahlii |
| US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| IL108915A0 (en) | 1993-03-18 | 1994-06-24 | Merck & Co Inc | Polynucleotide vaccine against influenza virus |
| FR2711670B1 (fr) | 1993-10-22 | 1996-01-12 | Pasteur Institut | Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite. |
| ATE475668T1 (de) | 1994-01-27 | 2010-08-15 | Univ Massachusetts Medical | Immunisierung durch impfung von dns transkriptionseinheit |
| JP3911010B2 (ja) | 1994-04-29 | 2007-05-09 | イムノ・アクテイエンゲゼルシヤフト | 必須領域に外来ポリヌクレオチドを有する組換えポックスウイルス |
| JPH11502222A (ja) | 1995-03-23 | 1999-02-23 | キャンタブ ファーマシューティカルズ リサーチ リミティド | 遺伝子供給用ベクター |
| WO1998000166A1 (en) | 1996-07-03 | 1998-01-08 | Merial, Inc. | Recombinant canine adenovirus (cav) containing exogenous dna |
| US6183752B1 (en) | 1997-02-05 | 2001-02-06 | Pasteur Merieux Serums Et Vaccins | Restenosis/atherosclerosis diagnosis, prophylaxis and therapy |
| EP1317559B1 (en) | 2000-04-28 | 2009-01-07 | St. Jude Children's Research Hospital | Dna transfection system for the generation of infectious negative strand rna virus |
| US20020095197A1 (en) | 2000-07-11 | 2002-07-18 | Lardo Albert C. | Application of photochemotherapy for the treatment of cardiac arrhythmias |
| CA2654178A1 (en) * | 2006-06-16 | 2007-12-27 | Dow Agrosciences Llc | Novel dna sequences, vectors and proteins of avian influenza hemagglutinin |
| EP2624864B1 (en) * | 2010-10-04 | 2017-12-06 | Massachusetts Institute of Technology | Hemagglutinin polypeptides, and reagents and methods relating thereto |
-
2011
- 2011-10-21 AR ARP110103916A patent/AR083533A1/es unknown
- 2011-10-22 ES ES11778762T patent/ES2798326T3/es active Active
- 2011-10-22 CN CN2011800617190A patent/CN103429611A/zh active Pending
- 2011-10-22 WO PCT/US2011/057406 patent/WO2012054907A2/en not_active Ceased
- 2011-10-22 EP EP11778762.2A patent/EP2630155B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2630155A2 (en) | 2013-08-28 |
| WO2012054907A3 (en) | 2012-06-21 |
| ES2798326T3 (es) | 2020-12-10 |
| EP2630155B1 (en) | 2020-04-15 |
| WO2012054907A2 (en) | 2012-04-26 |
| CN103429611A (zh) | 2013-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR083533A1 (es) | Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe | |
| AR107020A2 (es) | Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9) | |
| PE20180571A1 (es) | Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias | |
| ES2673556T3 (es) | Vacunas para el VHS-2 | |
| ES2691091T3 (es) | Vacuna conjugada de péptido antigénico de WT1 | |
| PE20140986A1 (es) | Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae | |
| AR094141A1 (es) | Composiciones y metodos para proteinas de accion prolongada | |
| AR105822A1 (es) | Análogos de insulina | |
| BRPI0923346A2 (pt) | Proteinas em super-helice antiparalela de cadeia simples | |
| MX2014006396A (es) | Vacunas contra el virus de la influenza y sus usos. | |
| MX356517B (es) | Polipéptidos de fusión de serpina y métodos de uso de los mismos. | |
| AR088737A1 (es) | Familia de toxinas inhibidoras de insectos activa contra insectos hemipteros y/o lepidopteros | |
| SI2280721T1 (en) | Indoleamine 2, 3-dioxygenase based immunotherapy | |
| BRPI0815578B8 (pt) | Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer) | |
| CO6210831A2 (es) | Nuevas proteinas h5 moleculas de acido nucleico y vectores que las codifican y su uso medicinal | |
| MX2019003116A (es) | Nueva vacuna contra la gripe porcina. | |
| AR090439A1 (es) | Lipopeptidos antimicrobianos cortos | |
| AR083839A1 (es) | Virus del sindrome reproductivo y respiratorio porcino (prrs) de los estados unidos y sus usos | |
| MX350306B (es) | Vacuna y metodos para reducir una infeccion por campylobacter. | |
| AR128395A2 (es) | Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9 | |
| NZ756128A (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
| PE20230343A1 (es) | Peptidos que estimulan respuestas inmunitarias antitumorales | |
| AR094725A1 (es) | Parvovirus 5a porcino, métodos de uso y vacuna | |
| MX363149B (es) | Vacunas de nucleoproteina de la influenza. | |
| CO2019005169A2 (es) | Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |